EGFR and lung carcinoma: For lung cancer cells resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), the use of DNMTi or HDACi can alter the epigenetic modifications of drug resistance-related genes, partially restoring the sensitivity of lung cancer cells to TKI (306, 322).